Xarelto, a new-generation blood thinner, has been linked to a number of complications, including fainting, itching, pain in the arms or legs, muscle pain, and muscle spasms. Uncontrollable internal bleeding is the most serious Xarelto side effect, as there currently exists no approved antidote for reversing the drug’s anticoagulant action.
Xarelto is a blood-thinning medication that was developed by Bayer and is marketed by Johnson & Johnson. It is used to:
Xarelto was approved by the U.S. Food & Drug Administration in 2011. In 2013, Bayer made $1.3 billion from sales of Xarelto. The medication has proven popular because it does not require patients to follow certain dietary restrictions or undergo regular blood monitoring, as is the case with a much older blood thinner called warfarin.
The Xarelto label includes a boxed warning regarding an increased risk of stroke following discontinuation of the drug in patients with atrial fibrillation. The boxed warning also notes that epidural or spinal hematomas have occurred in patients treated with Xarelto who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis.
Like any blood thinner, Xarelto can cause serious internal bleeding. However, no reversal agent has yet been approved to treat this dangerous Xarelto side effect. Even a minor trauma that results in bruising has the potential to be a serious event for Xarelto patients. By contrast, bleeding associated with warfarin can be stopped via the administration of vitamin K.
Contact your doctor if you experience any of the following Xarelto side effects, as they could be an indication of internal bleeding:
Xarelto users should speak with their doctor if they experience any of the following side effects:
The following Xarelto side effects require immediate medical attention:
Bernstein Liebhard LLP offers free legal reviews to victims of Xarelto bleeding side effects. To learn more, please call (888) 994-5118 to discuss your case with one of our attorneys.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.